W World Corp.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a WWHC research report →
About the company
W World Corp. is a biopharmaceutical firm dedicated to identifying and advancing innovative treatments for various metabolic and neurological conditions. Its research and development efforts specifically target ailments related to the brain-gut axis, pain and inflammation, autoimmune diseases, and gout.
- CEO
- Eric W. Fangmann
- IPO
- 1983
- Employees
- 2
- HQ
- North Las Vegas, NV, US
Price Chart
- Market Cap
- $80.24M
- P/E
- -8000.00
- P/S
- 0.00
- P/B
- -9649.82
- EV/EBITDA
- -8684.45
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 106.27%
- ROIC
- -334.78%
- Revenue
- $0 · 0.00%
- Net Income
- $-9,240 · 99.64%
- EPS
- $-0.00 · 100.00%
- Op Income
- $-9,240
- FCF YoY
- 0.00%
- 52W High
- $2.00
- 52W Low
- $0.50
- 50D MA
- $1.00
- 200D MA
- $1.03
- Beta
- 0.64
- Avg Volume
- 3
Get TickerSpark's AI analysis on WWHC
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our WWHC coverage
Recent articles, reports, and earnings notes.
No research on WWHC yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate WWHC report →Similar companies
Peers in the same neighborhood.